Closed

New pricing and payment models for cost-effective and affordable health innovations

HORIZON Research and Innovation Actions

Basic Information

Identifier
HORIZON-HLTH-2022-IND-13-03
Programme
A competitive health-related industry (2022)
Programme Period
2021 - 2027
Status
Closed (31094503)
Opening Date
October 5, 2021
Deadline
April 20, 2022
Deadline Model
single-stage
Budget
€2,000,000
Min Grant Amount
€2,000,000
Max Grant Amount
€2,000,000
Expected Number of Grants
1
Keywords
HORIZON-HLTH-2022-IND-13-03HORIZON-HLTH-2022-IND-13Computer sciences, information science and bioinformaticsHealth care sciences and services (including hospital administration, health care financing)Health policy and services

Description

Expected Outcome:

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 6 “Maintaining an innovative, sustainable and globally competitive health industry”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:

  • Health authorities and insurers adopt new payment models for health technologies, including pharmaceuticals.
  • Health industries anticipate better the marketing conditions for innovative health technologies. Patients and health care providers have faster access to innovative health technologies.
  • Health authorities, insurers and health care providers have affordable innovative health technologies both on short and longer terms.
Scope:

Applicants are requested to propose new value-based pricing and reimbursement models that can help ensure equitable access to effective, efficient, affordable, and sustainable health technologies, including medicines, while supporting innovation and industrial competitiveness. The research should tackle the issue globally and be based on a multidisciplinary approach combining economic science, political science and sociology. The proposals should not be limited to the study of cost-effectiveness analyses and thresholds in decision-making. They should also address long term intended and unintended consequences of pricing and reimbursement decisions. Moreover, they should consider the potential limitation of no-coverage decision for products with high budgetary impact. Applicant consortia should include regulators and public entities that are in charge of attributing value tags to health technologies, negotiating with health technology manufacturers and/or reimbursing medical costs. Differences between public and private sectors could be considered, as appropriate. Proposals should also consider citizens engagement and dialogue, for seeking wider input and support, and could encourage other social innovation approaches.

Applicants should propose activities in all of the following areas:

  • Affordability of health innovations.
  • Variety of pricing/payment schemes in the EU.
  • Cost-effectiveness and budget impact (including life-time indirect medical costs).
  • Impact of payment schemes (e.g. pay-for-performance/multi-annual instalments) on long-term competition in health technology markets, in particular the pharmaceutical market.
  • Potential influence of post-launch evidence-generation plans agreed with regulators and downstream decision makers (HTAs, payers) on the payment models.
  • Transparent and comprehensive assessment of technology and medicine development costs, taking into account public investments and incremental character of some innovations (e.g. new indications).
  • Development, integration and harmonisation of tools that allow for validation and revision of clinical evidence and cost-effectiveness, and long-term financial planning for effective and transparent decision-making.
  • New methods for definition of cost-effectiveness thresholds, integration of greener production and environmental impact, rational applications in real world contexts, comparative analysis of influence in decision-making and influence in the formulation of prices of technologies.
  • Potential equity issues derived by payment models and the measures for their mitigation.

Destination & Scope

Calls for proposals under this destination are directed towards the Key Strategic Orientation KSO-A ‘Promoting an open strategic autonomy by leading the development of key digital, enabling and emerging technologies, sectors and value chains’ of Horizon Europe’s Strategic Plan 2021-2024. Research and innovation supported under this destination should contribute to the impact area ‘A competitive and secure data-economy’ and in particular to the following expected impact, set out in the Strategic Plan for the health cluster: ‘EU health industry is innovative, sustainable and globally competitive thanks to improved up-take of breakthrough technologies and innovations, which makes the EU with its Member States more resilient and less dependent from imports with regard to the access to and supply of critical health technologies’. In addition, research and innovation supported under this destination could also contribute to the following impact areas: ‘Industrial leadership in key and emerging technologies that work for people’, ‘High quality digital services for all’, and ‘Good health and high-quality accessible health care’.

The health industry is a key driver for growth and has the capacity to provide health technologies to the benefit of patients and providers of health care services. The relevant value chains involve a broad variety of key players from supply, demand and regulatory sides. In addition, the path of innovation in health is long and complex. The development of novel health technologies is generally associated with uncertainties and market barriers due to expensive and risky development (e.g. attrition rate in pharmaceutical development), high quality and security requirements (e.g. clinical performance, safety, data privacy and cybersecurity) and market specificities (e.g. strong regulation, pricing and reimbursement issues). In addition, the growing concern about environmental issues is putting more pressure on this industry. Therefore, there is a need for research and innovation integrating various stakeholders to facilitate market access of innovative health technologies (medical technologies, pharmaceuticals, biotechnologies, digital health technologies).

In order to address these challenges, in particular green and digital transitions and proper supply of health technologies and products, destination 6 will focus on research and innovation activities that aim at:

  • Production of pharmaceuticals in compliance with the objectives of the European Green Deal.
  • Methodologies, guidelines and standards, assessment studies, and structuring activities adapted to digital solutions and interventions for GDPR compliant translation into health care practice, including inter-operability, cyber-security and data confidentiality.
  • Public authorities supported with better methodologies and interdisciplinary approaches to assess and value new health technologies and interventions.
  • Development of pharmaceutical products meeting unmet medical needs in the context of market failures.

In view of increasing the impact of EU investments under Horizon Europe, the European Commission welcomes and supports cooperation between EU-funded projects to enable cross-fertilisation and other synergies. This could range from networking to joint activities such as the participation in joint workshops, the exchange of knowledge, the development and adoption of best practices, or joint communication activities. Opportunities for potential synergies exist between projects funded under the same topic but also between other projects funded under another topic, cluster or pillar of Horizon Europe (but also with ongoing projects funded under Horizon 2020). In particular, this could involve projects related to European health research infrastructures (under pillar I of Horizon Europe), the EIC strategic challenges on health and EIT-KIC Health (under pillar III of Horizon Europe), or in areas cutting across the health and other clusters (under pillar II of Horizon Europe). For instance, with cluster 4 “Digital, Industry and Space” such as on industrial research and innovation infrastructures (pilot plants, testing and simulation facilities, open innovation hubs); additive manufacturing (3D/4D printing) and other production technologies (incl. bio manufacturing); safe, smart and sustainable materials.

Expected Impacts:

Proposals for topics under this destination should set out a credible pathway to contributing to maintaining an innovative, sustainable and globally competitive health industry, and more specifically to one or several of the following expected impacts:

  • Health industry in the EU is more competitive and sustainable, assuring European leadership in breakthrough health technologies and strategic autonomy in essential medical supplies and digital technologies, contributing to job creation and economic growth, in particular with small- and medium-sized enterprises (SMEs).
  • Health industry is working more efficiently along the value chain from the identification of needs to the scale-up and take-up of solutions at national, regional or local level, including through early engagement with patients, health care providers, health authorities and regulators ensuring suitability and acceptance of solutions.
  • European standards, including for operations involving health data, ensure patient safety and quality of healthcare services as well as effectiveness and interoperability of health innovation and productivity of innovators.
  • Citizens, health care providers and health systems benefit from a swift uptake of innovative health technologies and services offering significant improvements in health outcomes, while health industry in the EU benefits from decreased time-to-market.
  • Health security in the EU benefits from reliable access to key manufacturing capacity, including timely provision of essential medical supplies of particularly complex or critical supply and distribution chains, such as regards vaccines or medical radioisotopes.

Eligibility & Conditions

General conditions

General conditions

1. Admissibility conditions: described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.

Proposal page limits and layout: described in Part B of the Application Form available in the Submission System.

 

2. Eligible countries: described in Annex B of the Work Programme General Annexes.

A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.

In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding to support its participation in projects funded under the Health cluster.

 

3. Other eligibility conditions: described in Annex B of the Work Programme General Annexes.

 

4. Financial and operational capacity and exclusion: described in Annex C of the Work Programme General Annexes.

Award criteria, scoring and thresholds are described in Annex D of the Work Programme General Annexes.

Submission and evaluation processes are described in Annex F of the Work Programme General Annexes and the Online Manual.

Indicative timeline for evaluation and grant agreement: described in Annex F of the Work Programme General Annexes.

 

6. Legal and financial set-up of the grants: described in Annex G of the Work Programme General Annexes.

 

Specific conditions

7. Specific conditions: described in the specific topic of the Work Programme.

Support & Resources

Online Manual is your guide on the procedures from proposal submission to managing your grant.

Horizon Europe Programme Guidecontains the detailed guidance to the structure, budget and political priorities of Horizon Europe.

Funding & Tenders Portal FAQ – find the answers to most frequently asked questions on submission of proposals, evaluation and grant management.

Research Enquiry Service – ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.

Enterprise Europe Network – contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.

IT Helpdesk – contact the Funding & Tenders Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.

European IPR Helpdesk assists you on intellectual property issues.

CEN-CENELEC Research Helpdesk and ETSI Research Helpdesk – the European Standards Organisations advise you how to tackle standardisation in your project proposal.

The European Charter for Researchers and the Code of Conduct for their recruitment– consult the general principles and requirements specifying the roles, responsibilities and entitlements of researchers, employers and funders of researchers.

Partner Search Services help you find a partner organisation for your proposal.

National Contact Points (NCP) – contact your NCP for further assistance.

Latest Updates

Last Changed: August 8, 2022

 We recently informed the applicants about the evaluation results for their proposals submitted under this call. The results of the evaluation are as follows:

  • Number of proposals submitted (including proposals transferred from or to other calls): 88
  • Number of inadmissible proposals: 3
  • Number of ineligible proposals: 3
  • Number of above-threshold proposals: 62 
  • Total budget requested for above-threshold proposals: 333,100,753 EUR
Last Changed: August 8, 2022

We recently informed the applicants about the evaluation results for their proposals submitted under this call. The results of the evaluation are as follows:

  • Number of proposals submitted (including proposals transferred from or to other calls): 88
  • Number of inadmissible proposals: 3
  • Number of ineligible proposals: 3
  • Number of above-threshold proposals: 62 
  • Total budget requested for above-threshold proposals: 333,100,753 EUR
Last Changed: April 28, 2022

Call HORIZON-HLTH-2022-IND-13 closed on 21 April 2022. 89 proposals were submitted. The breakdown per topic is:

  • HORIZON-HLTH-2022-IND-13-01: 31 proposals
  • HORIZON-HLTH-2022-IND-13-02: 35 proposals
  • HORIZON-HLTH-2022-IND-13-03: 5 proposals
  • HORIZON-HLTH-2022-IND-13-04: 15 proposals
  • HORIZON-HLTH-2022-IND-13-05: 3 proposals

Evaluation results are expected to be communicated on Friday 5 August 2022 at the earliest.

Last Changed: April 28, 2022

Call HORIZON-HLTH-2022-IND-13 closed on 21 April 2022. 89 proposals were submitted. The breakdown per topic is:

  • HORIZON-HLTH-2022-IND-13-01: 31 proposals
  • HORIZON-HLTH-2022-IND-13-02: 35 proposals
  • HORIZON-HLTH-2022-IND-13-03: 5 proposals
  • HORIZON-HLTH-2022-IND-13-04: 15 proposals
  • HORIZON-HLTH-2022-IND-13-05: 3 proposals

Evaluation results are expected to be communicated on Friday 5 August 2022 at the earliest.

Last Changed: October 6, 2021
The submission session is now available for: HORIZON-HLTH-2022-IND-13-01(HORIZON-RIA), HORIZON-HLTH-2022-IND-13-04(HORIZON-CSA), HORIZON-HLTH-2022-IND-13-02(HORIZON-RIA), HORIZON-HLTH-2022-IND-13-05(HORIZON-CSA), HORIZON-HLTH-2022-IND-13-03(HORIZON-RIA)
New pricing and payment models for cost-effective and affordable health innovations | Grantalist